The Novo Nordisk Golden Ticket – BioLabs European Award is granted to top-tier biotech innovators tackling transformative challenges in cardiometabolic and obesity-related diseases. This exclusive award provides Halo Therapeutics with direct engagement with Novo Nordisk’s scientific and business leaders offering mentorship, strategic insights, and unparalleled networking opportunities to fast-track its obesity research. In addition, the award includes a fully sponsored lab bench, workspace, and BioLabs membership for one year – a critical boost for early-stage biotech ventures.

"Receiving the Novo Nordisk Golden Ticket is a tremendous honour and a powerful endorsement of the ground-breaking work in our team is doing in obesity drug development,” said Daniel Fitzgerald, PhD, CEO of Halo Therapeutics.  “With Novo Nordisk’s support, we are poised to accelerate our research and drive meaningful innovation in obesity therapy.”

“The founders of Halo, Daniel Fitzgerald, Imre Berger and Christiane Schaffitzel have world leading structural biology capabilities and drug development expertise and we wanted to back this team as they developed important medicines,” said Johnathan Matlock, CEO of Halo Investor Empirical Ventures. “This is an exceptional prize for Halo and provides significant mentoring and support from some of the world's leading scientific teams at Novo. This will help to guide the development of their latest assets and could significantly aid the development of the next blockbuster drugs for the obesity market.”

The award further strengthens Halo's position as a rising force in Europe’s biotech ecosystem, and provides a critical pathway for high-impact collaborations and strategic partnerships.

For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.